[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643503":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":38,"responsibleParty":56,"collaborators":58,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":18,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":94,"whyStopped":18,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"health-related arm","EXPERIMENTAL","Participants will receive an health-related message included in the biological results form. A short graphical illustration will indicate the patient-risk level according the biological results and video detailing national recommendations.\n\nHCPs will receive a SIGNAL BIO message which was elaborated on evidence-based treatments and\u002For strategy for patients with diabetes.",[13],"Other: Health-related messages",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Participants will get as in the routine care, no message will be disseminated for this group.",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":18},"Health-related messages","Patient will be included in the intervention according to the laboratory's randomization arm.The intervention consists in delivering patient information messages in laboratory reports, providing access to an educational video for patients and a specific message for the prescribing physician in the intervention arm, without modifying patient care.",[9],[25],{"name":26,"affiliation":5,"role":27},"Samy Hadjadj, MD","PRINCIPAL_INVESTIGATOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":32,"email":33},"Samy Hadjadj, PU-PH","CONTACT","+33244768545","samy.hadjadj@univ-nantes.fr",{"name":35,"role":31,"phone":36,"phoneExt":18,"email":37},"Sonia Brinet","+33253526126","sonia.brinet@chu-nantes.fr",[39],{"facility":40,"status":18,"city":41,"state":18,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Biogroup laboratories","Nantes","44000","France","FR",{"type":46,"coordinates":47},"Point",[48,49],-1.55336,47.21725,{"lat":49,"lon":48},[52],{"name":53,"role":31,"phone":54,"phoneExt":18,"email":55},"Claire Vignault, MD","0645644018","claire.vignault@biogroup.fr",{"type":57,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[59,61,63,65,68],{"name":60,"class":6},"Hospices Civils de Lyon",{"name":62,"class":6},"University Hospital, Toulouse",{"name":64,"class":6},"University Hospital, Tours",{"name":66,"class":67},"Biogroup Laboratoire de biologie médicale","UNKNOWN",{"name":69,"class":67},"Santé publique France-InVS (Institut National de Veille sanitaire)","100643503","implementation-trial-in-patients-with-renal-failure-and-diabetes-for-major-adverse-renal-and-cardiovascular-events-100643503",false,"NCT07634718","Implementation Trial In patieNts With rEnal failuRe and diAbetes for Major Adverse reNal and Cardiovascular Events","ITINERANCE","Main inclusion criteria:\n\n* Subject attending a ML participating to the study\n* Subject presenting a HbA1c ≥ 6.5% and an estimated GFR (CKD-EPI formula) in the range 60 to 15 ml\u002Fmin (included) and\u002For albumin to creatinine ratio ≥ 300 mg albumin\u002Fg creatinine (or 30 mg\u002Fmmol creatinine), on the same biological determination.\n\nMain exclusion criteria:\n\n* Subject previously identified as opposed to the use of their medical data and\u002For access of their SNDS data,\n* Subject not registered to the French social security system,\n* Subject with estimated GFR \\\u003C 15 ml\u002Fmin on the day of inclusion","ALL","18 Years","80 Years",{"count":81,"type":82},125000,"ESTIMATED","INTERVENTIONAL",[85],"NA","The goal of this clinical study is to establish if the use of public health-related messages, designed and disseminated to a targeted population, will result in tangible improvements in patient outcomes and healthcare practices.\n\nSpecific health-related messages oriented towards patients, through their biological results and HealthCare Professionals (HCPs), will be sent to participants included in the intervention group. The control group will not receive any health-related message (routine care).\n\nThe aim is to evaluate if this intervention leads to differences in Major Adverse Renal and Cardiovascular Events (MARCE), compared to routine care (no dissemination of health messages) in patients suffering in diabetes and renal failure.",[88,89],"Diabetes","Renal Failure , Chronic",[91,92,93],"implementation","heatlh-related message","Renal and cardiovascular event","NOT_YET_RECRUITING","2026-06-02",{"date":97,"type":98},"2026-06-09","ACTUAL",{"date":100,"type":82},"2026-06",{"date":102,"type":82},"2032-06",{"name":5,"class":6},1]